ELC 301
Alternative Names: CAR20(NAP)-T; ELC-301Latest Information Update: 05 Jun 2024
At a glance
- Originator Elicera Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II B-cell lymphoma
Most Recent Events
- 01 May 2024 Phase-I/II clinical trials in B-cell lymphoma (In adolescents, In adults, In children, In the elderly, Second-line therapy or greater) in Sweden (Parenteral) (NCT06002659)
- 24 Feb 2022 Elicera Therapeutics has patent protection for iTANK tevhnology (Elicera Therapeutics pipeline, Febuary 2022)
- 24 Feb 2022 Preclinical trials in B-Cell Lymphoma in Sweden (Parenteral) (Elicera Therapeutics pipeline, Febuary 2022)